The new candidato a fármaco RCI001 currently under desarrollo delivers antiinflamatorio effects through the selective modulation of multifunctional signaling molecules.
Además, it has shown improvement in secreción lagrimal function, and actualmente está being developed as an eye drop with the goal of entering ensayo clínicos nacionalally and internacionally el próximo año. RCI001 played a key role in being seleccionada for the 'I+D Rediscovery Project' and other programas.